Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. uri icon

authors

  • Wohlford, George F
  • Chiabrando, Juan Guido
  • Bressi, Edoardo
  • Thomas, Georgia
  • Ho, Ai-Chen
  • Marawan, Amr A
  • Dell, Megan
  • Trankle, Cory R
  • Turlington, Jeremy
  • Markley, Roshanak
  • Abbate, Antonio
  • Van Tassell, Benjamin W
  • Hayley Billingsley, PhD, RD, CEP
  • Kadariya, Dinesh
  • Canada, Justin M
  • Carbone, Salvatore
  • Mihalick, Virginia L
  • Bonaventura, Aldo
  • Vecchié, Alessandra

publication date

  • January 1, 2020